Loading...

NLS Pharmaceutics AG

NLSPW•NASDAQ
Healthcare
Biotechnology
$0.02
$-0.01(-33.57%)

NLS Pharmaceutics AG (NLSPW) Stock Overview

Explore NLS Pharmaceutics AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.7/100

Key Financials

Market Cap8.7M
P/E Ratio-50.98
EPS (TTM)N/A
ROE0.23%

AI Price Forecasts

1 Week$0.03
1 Month$0.02
3 Months$0.03
1 Year TargetN/A

NLSPW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of NLS Pharmaceutics AG (NLSPW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -50.98 and a market capitalization of 8.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NLSPWStats details for NLSPW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NLSPWAnalyst Recommendations details for NLSPW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

CEO

Mr. Alexander Zwyer M.B.A.

Employees

3

Headquarters

The Circle 6, Zurich

Founded

2021

Frequently Asked Questions

;